TY - JOUR

T1 - Sertindole for schizophrenia

AU - Lewis, Ruth

AU - Bagnall, Anne-Marie

AU - Leitner, Maria

PY - 2005/7/20

Y1 - 2005/7/20

N2 - This review includes three studies with a total of 1104 participants. We excluded two large important studies because they did not report any usable data. The three that were included suggested that sertindole (20 mg/day) was more antipsychotic than placebo, as acceptable as placebo (in terms of various adverse events including movement disorde r s and somnolence) and better tole r ated than haloperidol. Sertindole was associated with fewer movement disorders than h aloperidol, but was shown to cause more weight gainand the possible side e ffect of male sexual dysfunction. Cardiac problems (QTc intervals of at least 500 msec) were evident even in the randomised trials. Sertindole used at 16 mg/day (reported to be the most optimal dose by one study) caused more rhinitis than haloperidol.

AB - This review includes three studies with a total of 1104 participants. We excluded two large important studies because they did not report any usable data. The three that were included suggested that sertindole (20 mg/day) was more antipsychotic than placebo, as acceptable as placebo (in terms of various adverse events including movement disorde r s and somnolence) and better tole r ated than haloperidol. Sertindole was associated with fewer movement disorders than h aloperidol, but was shown to cause more weight gainand the possible side e ffect of male sexual dysfunction. Cardiac problems (QTc intervals of at least 500 msec) were evident even in the randomised trials. Sertindole used at 16 mg/day (reported to be the most optimal dose by one study) caused more rhinitis than haloperidol.

U2 - 10.1002/14651858.CD001715.pub2

DO - 10.1002/14651858.CD001715.pub2

M3 - Article

VL - 2005

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1469-493X

IS - 3

M1 - CD001715

ER -